Glutamate-based Therapies for Psychiatric Disorders [electronic resource] / edited by Phil Skolnick.

Call Number
615.78
Title
Glutamate-based Therapies for Psychiatric Disorders edited by Phil Skolnick.
Physical Description
XIV, 178 p. online resource.
Series
Milestones in Drug Therapy
Contents
N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression -- Ionic Glutamate Modulators in Depression (Zinc, Magnesium) -- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy -- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors -- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders -- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia -- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia -- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence -- Metabotropic Approaches to Anxiety.
Summary
Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.
Added Author
Skolnick, Phil. editor.
SpringerLink (Online service)
Subject
MEDICINE.
NEUROSCIENCES.
PHARMACOLOGY.
PSYCHIATRY.
PSYCHOPHARMACOLOGY.
Medicine & Public Health.
Psychopharmacology.
Pharmacology/Toxicology.
Psychiatry.
Neurosciences.
Multimedia
  • Libraries with this item
Total Ratings: 0
No records found to display.
 
 
 
03297nam a22005295i 4500
001
 
 
vtls001568609
003
 
 
VRT
005
 
 
20170831184100.0
007
 
 
cr nn 008mamaa
008
 
 
170831s2010    sz |    s    |||| 0|eng d
020
$a 9783034602419 $9 978-3-0346-0241-9
024
7
$a 10.1007/978-3-0346-0241-9 $2 doi
035
$a (DE-He213)978-3-0346-0241-9
039
9
$y 201708311841 $z santha
050
4
$a RM315-334
072
7
$a MMGW $2 bicssc
072
7
$a MED105020 $2 bisacsh
082
0
4
$a 615.78 $2 23
245
1
0
$a Glutamate-based Therapies for Psychiatric Disorders $h [electronic resource] / $c edited by Phil Skolnick.
264
1
$a Basel : $b Birkhäuser Basel : $b Imprint: Birkhäuser, $c 2010.
300
$a XIV, 178 p. $b online resource.
336
$a text $b txt $2 rdacontent
337
$a computer $b c $2 rdamedia
338
$a online resource $b cr $2 rdacarrier
347
$a text file $b PDF $2 rda
490
1
$a Milestones in Drug Therapy
505
0
$a N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression -- Ionic Glutamate Modulators in Depression (Zinc, Magnesium) -- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy -- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors -- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders -- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia -- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia -- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence -- Metabotropic Approaches to Anxiety.
520
$a Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.
650
0
$a MEDICINE.
650
0
$a NEUROSCIENCES.
650
0
$a PHARMACOLOGY.
650
0
$a PSYCHIATRY.
650
0
$a PSYCHOPHARMACOLOGY.
650
1
4
$a Medicine & Public Health.
650
2
4
$a Psychopharmacology.
650
2
4
$a Pharmacology/Toxicology.
650
2
4
$a Psychiatry.
650
2
4
$a Neurosciences.
700
1
$a Skolnick, Phil. $e editor.
710
2
$a SpringerLink (Online service)
773
0
$t Springer eBooks
776
0
8
$i Printed edition: $z 9783034602402
830
0
$a Milestones in Drug Therapy
856
4
0
$u http://dx.doi.org/10.1007/978-3-0346-0241-9
912
$a ZDB-2-SBL
950
$a Biomedical and Life Sciences (Springer-11642)
999
$a VIRTUA               
No Reviews to Display
Summary
Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.
Contents
N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression -- Ionic Glutamate Modulators in Depression (Zinc, Magnesium) -- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy -- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors -- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders -- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia -- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia -- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence -- Metabotropic Approaches to Anxiety.
Subject
MEDICINE.
NEUROSCIENCES.
PHARMACOLOGY.
PSYCHIATRY.
PSYCHOPHARMACOLOGY.
Medicine & Public Health.
Psychopharmacology.
Pharmacology/Toxicology.
Psychiatry.
Neurosciences.
Multimedia